Age-related differences in levodopa dynamics in Parkinson's: Implications for motor complications

Brain

Volumn 129, Issue 4, 2006, Pages 1050-1058

  Sossi, Vesna ^a,b   De La Fuente Fernández, Raúl ^c   Schulzer, Michael ^a   Adams, John ^b   Stoessl, Jon ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Pacific Parkinson's Research Centre   (Canada)

^c Universidad de La Coruña   (Spain)

Author keywords

Age dependence; DA turnover; Dopaminergic system; Motor complications

Indexed keywords

ANTIPARKINSON AGENT; DOPAMINE; LEVODOPA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DISEASE SEVERITY; DOPAMINE METABOLISM; DOPAMINE RELEASE; DYNAMICS; FEMALE; HUMAN; IN VIVO STUDY; MALE; MOTOR DYSFUNCTION; PARKINSON DISEASE; PRIORITY JOURNAL; PUTAMEN; STATISTICAL SIGNIFICANCE;

EID: 33645055382     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awl028     Document Type: Article

References (42)

1. Barrio JR, Huang SC, Melega WP, Yu DC, Hoffman JM, Schneider JS, et al. 6-[18F]fluoro-L-dopa probes dopamine turnover rates in central dopaminergic structures. J Neurosci Res 1990; 27: 487-93.
2. Cordes M, Snow BJ, Cooper S, Schulzer M, Pate BD, Ruth TJ, et al. Age dependent decline of nigrostriatal dopaminergic function: a positron emission tomographic study of grandparents and their grandchildren. Ann Neurol 1994; 36: 667-70.
3. de la Fuente-Fernández R, Pal PK, Vingerhoets FJG, Kishore A, Schulzer M, Mak EK, et al. Evidence for impaired presynaptic dopamine function in parkinsonian patients with motor fluctuations. J Neural Transm 2000; 107: 49-57.
4. de la Fuente-Fernández R, Lu J-Q, Sossi V, Jivan S, Schulzer M, Holden JE, et al. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. Ann Neurol 2001; 49: 298-303.
5. de la Fuente-Fernandez R, Lim AS, Sossi V, Adam MJ, Ruth TJ, Calne DB, et al. Age and severity of nigrostriatal damage at onset of Parkinson's disease. Synapse 2003; 47: 152-8.
6. de la Fuente-Fernández R, Schulzer M, Mak E, Calne DB, Stoessl A. Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model. Brain 2004a; 127: 888-99.
7. de la Fuente-Fernandez R, Sossi V, Huang Z, Furtado S, Lu JQ, Calne DB, et al. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain 2004b; 127: 2747-54.
8. 18F]Fluoro-L-DOPA PET studies of the turnover of dopamine in MPTP-induced parkinsonism in monkeys. Synapse 1998; 29: 225-32.
9. Eidelberg D, Takikawa S, Dhawan V, Chaly T, Robeson W, Dahl R, et al. Striatal 18F-dopa uptake: absence of an aging effect. J Cereb Blood Flow Metab 1993; 13: 881-8.
10. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991; 114: 2283-301.
11. Fowler JS, Volkow ND, Wang GJ, Logan J, Pappas N, Shea C, et al. Age-related increases in brain monoamine oxidase B in living healthy human subjects. Neurobiol Aging 1997; 18: 431-5.
12. Frey KA, Koeppe RA, Kilbourn MR, Vander Borght TM, Albin RL, Gilman S, et al. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Ann Neurol 1996; 40: 873-84.
13. Gjedde A. High- and low-affinity transport of D-glucose from blood to brain. J Neurochem 1981; 36: 1436-71.
14. Gjedde A. Calculation of glucose phoshorylation from brain uptake of glucose analogues in vivo: a re-examination. Brain Res 1982; 357: 237-74.
15. Granérus AK, Carlsson A, Svanborg A. The aging neuron - influence on symptomatology and therapeutic response in Parkinson's syndrome. In: Poirier LJ, Sourkes TL, Bedard PJ, editors. Advances in neurology. Vol. 24, New York: Raven Press; 1979. p. 327-35.
16. Haycock JW, Becker L, Ang L, Furukawa Y, Hornykiewicz O, Kish SJ. Marked disparity between age-related changes in dopamine and other presynaptic dopaminergic markers in human striatum. J Neurochem 2003; 87: 574-85.
17. Hornykiewicz O. Brain neurotransmitter changes in Parkinson's disease. In: Marsden CD, Fahn S, editors. Movement disorders. London: Butterworth; 1982. p. 41-58.
18. Kish SJ, Shannak K, Rajput A, Deck JHN, Hornykiewicz O. Aging produces a specific pattern of striatal dopamine loss: implications for the etiology of idiopathic Parkinson's disease. J Neurochem 1992; 58: 642-8.
19. Kops ER, Storb SH, Herzog HR, Bauer A. Age dependency of cortex values before and after partial volume correction in PET data. Nuclear Science Symposium Conference Record. IEEE Vol. 2: 2002. p. 850-852
20. Kostic V, Przedborski S, Flaster E, Sternic N. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology 1991; 41: 202-5.
21. Kumakura Y, Vernaleken I, Grunder G, Bartenstein P, Gjedde A, Cumming P. PET studies of net blood-brain clearance of FDOPA to human brain: age-dependent decline of [18F]fluorodopamine storage capacity. J Cereb Blood Flow Metab 2005; 25: 807-19.
22. Kumar MJ, Andersen JK. Perspectives on MAO-B in aging and neurological disease: where do we go from here? Mol Neurobiol 2004; 30: 77-89.
23. Kuwabara H, Cumming P, Yasuhara Y, Leger GC, Guttman M, Diksic M, et al. Dopamine turnover is increased in striatum of patients with Parkinson's disease. Brain 1993; Sendai Japan, May 22-28.
24. Lee CS, Samii A, Sossi V, Ruth TJ, Schulzer M, Holden JE, et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol 2000; 47: 493-503.
25. Lee CS, Schulzer M, de la Fuente-Fernandez R, Mak E, Kuramoto L, Sossi V, et al. Lack of regional selectivity during the progression of Parkinson disease: implications for pathogenesis. Arch Neurol 2004; 61: 1920-5.
26. Marsden CD, Parkes JD, Quinn N. Fluctuations of disability in Parkinson's disease - clinical aspects. In: Marsden CD, Fahn S, editors. Movement disorders. London: Butterworth; 1982. p. 96-122.
27. Marsden CD, Parkes JD. On-off effects in patients with Parkinsons disease on chronic levodopa therapy. Lancet 1976; 1: 292-6.
28. Martin WRW, Palmer MR, Patlak CS, Calne DB. Nigrostriatal function in man studied with positron emission tomography. Ann Neurol 1989; 26: 535-42.
29. McGeer PL, McGeer EG, Suzuki JS. Aging and extrapyramidal function. Arch Neurol 1977; 34: 33-5.
30. 18F]fluoro-L-DOPA input curves with and without carbidopa and in hemi-MPTP lesioned monkeys. Appl Rad Isot 1991; 42: 847-54.
31. Obeso JA, Rodrigues-Oroz MC, Chana P, Lera G, Rodriguez M, Olanow CW. The evolution and origin of motor complications in Parkinson's disease. Neurology 2000; 55: S13-20.
32. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 1983; 3: 1-7.
33. Sawle GV, Colebatch JG, Shah A, Brooks DJ, Marsden CD, Frackowiak RS. Striatal function in normal aging: implications for Parkinson's disease. Ann Neurol 1990; 28: 799-804.
34. Sossi V, Oakes TR, Chan GL, Schulzer M, Ruth TJ. Quantitative comparison of three- and two-dimensional PET with human brain studies. J Nucl Med 1998; 39: 1714-9.
35. Sossi V, Doudet DJ, Holden JE. A reversible tracer analysis approach to the study of effective dopamine turnover. J Cereb Blood Flow Metab 2001; 21: 469-76.
36. Sossi V, de la Fuente-Fernãndez R, Holden JE, Doudet DJ, McKenzie J, Stoessl AJ, et al. Increase in dopamine turnover occurs early in Parkinson's disease: evidence from a new modeling approach to PET 18F-fluorodopa data. J Cereb Blood Flow and Metab 2002; 22: 232-39.
37. occ and the [18F]fluorodopa plasma input uptake rate constant Ki. J Cereb Blood Flow Metab 2003; 23: 301-9.
38. Sossi V, de la Fuente-Fernandez R, Holden JE, Schulzer M, Ruth TJ, Stoessl J. Changes of dopamine turnover in the progression of Parkinson's disease as measured by positron emission tomography: their relation to disease-compensatory mechanisms. J Cereb Blood Flow Metab 2004; 24: 869-76.
39. 18F-fluorodopa uptake rate and dopamine turnover PET markers and implications for Parkinson's disease progression. In: Proceedings of the XXIInd International Symposium on Cerebral Blood Flow, Metabolism, and Function, June 7-11, 2005, Amsterdam, The Netherlands, CDROM.
40. Spinks TJ, Jones T, Bailey DJ, Townsend DW, Grootoonk S, Bloomfield PM, et al. Physical performance of a positron tomograph for brain imaging with retractable septa. Phys Med Biol 1992; 37: 1637-55.
41. Stocchi F, Vacca L, Ruggieri S, Olanow CW. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol 2005; 62: 905-10.
42. Woods RP, Mazziotta JC, Cherry SR. MRI-PET registration with automated algorithm. J Comput Assist Tomogr 1993; 17: 536-46.